Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Vernakalant - Correvio Pharma

Drug Profile

Vernakalant - Correvio Pharma

Alternative Names: Brinavess; Kynapid; MK-6621; RSD-1235; Vernakalant-hydrochloride

Latest Information Update: 05 Sep 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cardiome Pharma
  • Developer Aspen Pharmacare; ATCO Laboratories; Cipher Pharmaceuticals; Correvio Pharma
  • Class Anisoles; Antiarrhythmics; Cyclohexanes; Pyrrolidines; Small molecules
  • Mechanism of Action Potassium channel antagonists; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Atrial fibrillation

Most Recent Events

  • 03 Sep 2019 Efficacy and adverse events data from the post-authorisation SPECTRUM study in Atrial fibrillation released by Correvio Pharma
  • 25 Jul 2019 The US FDA sets PDUFA date of December 24, 2019 for NDA review for Atrial fibrillation
  • 25 Jul 2019 The US FDA accepts the resubmitted NDA for Atrial fibrillation for review
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top